<!DOCTYPE html>
<html manifest="manifest.manifest">
<head>
	<meta http-equiv=Content-Type content="text/html; charset=utf-8">
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
  
	<meta name=Generator content="Microsoft Word 14 (filtered)">
		<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<link rel="stylesheet" href="mystyle.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>
	<script>
	    		$(function(){
			$("[data-role='header'], [data-role='footer']").toolbar();
		});
  	  $(document).one('pagebeforecreate', function () {
	        $('input[data-type="search"]').val("");
	    	        $.get("panel.html", function (data2) {
            $.mobile.pageContainer.prepend(data2);
              $("[data-role=panel]").panel().enhanceWithin();
        }, "html");
	           $.get("header.html", function (data) {
      $.mobile.pageContainer.prepend(data);
      $("[data-role='header']").toolbar().enhanceWithin();
    }, "html");
    $.get("footer.html", function (data) {
      $.mobile.pageContainer.append(data);
      $("[data-role='footer']").toolbar().enhanceWithin();
    }, "html");
        $('.WordSection1').wrap('<div role="main" class="ui-content">');
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $.mobile.pageContainer.enhanceWithin();
	  });
	        $(document).bind( "pagechange", function( ) {
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $('.tableCont').enhanceWithin();
      } );
			// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}</script>      
	





	






  
  
  	
</head>
<body lang=EN-GB link=blue vlink=purple>
	
<div data-role="page">
	<div role="main" class="ui-content">
<div class=WordSection1>
<h1 style='margin-bottom:12.0pt'><span lang=EN-US>Inflammatory arthritis and
connective tissue disease</span></h1>
<h2><i><span lang=EN-US>Executive summary</span></i></h2>
<h2><span lang=EN-US>Introduction</span></h2>
<p class=MsoNormal><span lang=EN-US>Rheumatological disorders are difficult to
diagnose accurately in our setting and can be difficult to treat, as we are
limited by the poor availability of tests and treatments. They are also not
common. Despite this, we are able to improve the quality of life and prognosis
of most of the patients with the medications we have available. </span></p>
<p class=MsoNormal><span lang=EN-US>Rheumatoid arthritis is the most common
condition seen. It is a symmetric, inflammatory, peripheral polyarthritis.
Untreated, it leads to joint destruction and disability. </span></p>
<p class=MsoNormal><span lang=EN-US>Other connective tissue disorders are much
less common. However, similar principles can be used to care for these
patients. </span></p>
<h2><span lang=EN-US>Target users</span></h2>
<p class=MsoListParagraph style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Doctors</span></p>
<h2><span lang=EN-US>Target area of use </span></h2>
<p class=MsoListParagraph style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Outpatient department</span></p>
<h2><span lang=EN-US>Key areas of focus / New additions / Changes </span></h2>
<p class=MsoNormal><span lang=EN-US>This guideline outlines an approach to
connective tissue and inflammatory conditions in our setting. It describes the
use of methotrexate (the only available DMARD in our setting) and the clinical
disease activity index for monitoring progress.</span></p>
<h2><span lang=EN-US>Limitations</span></h2>
<p class=MsoNormal><span lang=EN-US>We have no access to autoantibodies and
other diagnostic tests. We cannot do CRP routinely. </span></p>
<p class=MsoNormal><span lang=EN-US>We have limited access to drugs and no
access to biologicals.</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2 style='margin-bottom:6.0pt'><span lang=EN-US>Presenting symptoms and signs</span></h2>
<p class=MsoNormal><span lang=EN-US>Rheumatoid arthritis presents with joint
pain and swelling of the peripheral joints (affecting at least 3 joints), and
morning stiffness, all lasting at least 6 weeks. Other conditions such as
psoriasis, inflammatory bowel disease, SLE should be absent. It is often
gradual in onset, but may be intermittent at the beginning. Very occasionally,
rheumatoid arthritis may present with a persistent monoarthritis. In these
cases, septic arthritis, gout and other explanations must be excluded until a
polyarthritis develops. </span></p>
<p class=MsoNormal><span lang=EN-US>Extra-articular features of rheumatoid
arthritis include anaemia, fatigue, pericarditis, rashes, eye complications,
neuropathy, splenomegaly, Sjogren’s syndrome, vasculitis and others.
Alternatively, these and other systemic features may reflect another connective
tissue disorder. </span></p>
<h2 style='margin-bottom:6.0pt'><span lang=EN-US>Examination findings</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Painful, tender, swollen joints – especially the
proximal interphalangeal and metocarpophalangeal joints, the wrists, elbows,
shoulders and knees. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Typical rheumatoid deformities may be seen in
long-standing untreated cases. </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>C-spine pain and stiffness, which may eventually
lead to instability. </span></p>
<p class=MsoNormal><span lang=EN-US>Where an alternative diagnosis is
suspected, examine carefully in all systems – paying particular attention to
dermatological and musculoskeletal features. </span></p>
<h2 style='margin-bottom:6.0pt'><span lang=EN-US>Investigations</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Plain films of affected joints – may show
osteopenia, joint space narrowing and bone erosions. However, they are not
helpful if the diagnosis is clinically clear. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Rheumatoid factor – found in 70-80% of patients
(and in 5-10 % of healthy people and 20-30 % of patients with other
inflammatory conditions). Helpful, but not essential to the diagnosis. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>ESR – used for monitoring disease activity.</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>U&amp;Es, LFTs and FBC – useful to establish
baseline values for patients who will start methotrexate.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Other tests such as CK, U&amp;Es, HIV may be
important in excluding alternative diagnoses. </span></p>
<h3><span lang=EN-US>Further investigation where diagnosis unclear</span></h3>
<p class=MsoNormal><span lang=EN-US>Further investigations are not available in
the Gambia. If patients are interested and able, there are most investigations available
in Dakar and a referral should be made to Professor Pouye at Hôpital Le Dantec.
</span></p>
<h2 style='margin-bottom:6.0pt'><span lang=EN-US>Management</span></h2>
<p class=MsoNormal><span lang=EN-US>Patients with probable rheumatoid arthritis
and raised ESR should be started on disease modifying treatment (DMARD) as soon
as possible. </span></p>
<p class=MsoNormal><span lang=EN-US>All patients without contraindications
should start on methotrexate. </span></p>
<p class=MsoNormal><span lang=EN-US>Contraindications include: </span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Women who are pregnant or who want to be
pregnant. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Patients with liver disease</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Patients with severe renal impairment (eGFR &lt;
30 ml/min)</span></p>
<p class=MsoNormal><span lang=EN-US>The presence of respiratory disease is a
relative contraindication, so if there are respiratory symptoms, a chest X-ray
is helpful to exclude TB or other relevant concerns. </span></p>
<h3><span lang=EN-US>Disease modifying treatment (DMARD)</span></h3>
<p class=MsoNormal><span lang=EN-US>Start with <b>methotrexate</b> 7.5-15 mg
once per week and titrate up as tolerated. Patients who are older, less heavy
and with reduced renal function (eGFR &lt; 60 ml/min) should have the lower
doses. Increase approximately every 4 weeks to a target dose of 15-25 mg once
per week. If these doses are ineffective, the bioavailability can be increased
without increasing gastrointestinal side effects by dividing the dose into 2
(taken on the same day once per week). </span></p>
<p class=MsoNormal><span lang=EN-US>Patients on methotrexate should have FBC
and LFTs checked once every 3 months. A chest X-ray should be done if there is
any suggestion of respiratory symptoms. </span></p>
<p class=MsoNormal><span lang=EN-US>Patients on methotrexate should take folic
acid daily at a dose of 1 mg OD. As we have only 5 mg tablets, dosing once per
week is adequate. </span></p>
<p class=MsoNormal><span lang=EN-US>Methotrexate should be continued at an
effective rate for 3-6 months after the disease enters remission. After this,
the dose can be titrated down to the lowest effective level. </span></p>
<p class=MsoNormal><span lang=EN-US>Combination DMARD treatment can be used for
patients who continue to have high disease activity after 3-6 months of
treatment with methotrexate. The methotrexate is continued and <b>sulfasalazine</b>
and <b>hydroxychloroquine</b> are added. Sulfasalazine and hydroxychloroquine
can also be used in combination for patients that cannot take methotrexate. </span></p>
<p class=MsoNormal><span lang=EN-US>Sulfasalazine is started at 500 mg BD and
increased by 500 mg each week to a dose of 1500 mg BD. </span></p>
<p class=MsoNormal><span lang=EN-US>Hydroxychloroquine is given at a dose of
400 mg OD (maximum of 5 mg/kg/day). </span></p>
<h3><span lang=EN-US>Symptomatic treatment</span></h3>
<p class=MsoNormal><span lang=EN-US>NSAIDS rapidly reduce inflammation and
provide pain relief. They should be used for all patients with active disease
at maximal anti-inflammatory doses for at least 2 weeks before being withdrawn
gradually. Use <b>ibuprofen</b> 800 mg QDS (ibuprofen is more effective and has
fewer gastric side effects than diclofenac). Consider also given omeprazole 20
mg OD for patients who also receive steroid treatment. </span></p>
<p class=MsoNormal><span lang=EN-US>Steroids can be used to rapidly control
disease in patients with more severe disease or in patients for whom NSAID
treatment is ineffective. Give <b>prednisolone</b> 20 mg OD for 1 month. Reduce
the dose gradually to a maintenance level of 5-10 mg OD once symptoms settle
and wean off completely within 4 months. </span></p>
<p class=MsoNormal><span lang=EN-US>These treatments can be repeated as
necessary for patients experiencing flares of their disease. </span></p>
<h3><span lang=EN-US>Monitoring disease activity</span></h3>
<p class=MsoNormal><span lang=EN-US>Various scores are available for monitoring
disease activity in rheumatoid arthritis. The Clinical Disease Activity
Indicator (CDAI) is simple to calculate and is suitable for our setting. </span></p>
<p class=MsoNormal><span lang=EN-US>28 joints are reviewed – 10 proximal
interphalangeal joints, 10 metocarpophalangeal joints, 2 wrists, 2 elbows, 2
shoulders and 2 knees. Each should be examined for swelling and tenderness.
Estimate out of 10 (where 0 is completely well and 10 is as ill as possible)
how ill you think the patient is. Ask the patient the same question. </span></p>
<p class=MsoNormal><span lang=EN-US>Now add the number of swollen joints, the
number of tender joints, your assessment and the patient’s assessment. This
gives a score out of 76.</span></p>
<div class="tableCont">
  <table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='margin-left:56.45pt;border-collapse:collapse;border:none'>
 <tr>
  <td width=189 valign=top style='width:5.0cm;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Activity level</span></b></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>CDAI score</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=189 valign=top style='width:5.0cm;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Remission</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&lt; 2.8</span></p>
  </td>
 </tr>
 <tr>
  <td width=189 valign=top style='width:5.0cm;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Low disease activity</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>3-10</span></p>
  </td>
 </tr>
 <tr>
  <td width=189 valign=top style='width:5.0cm;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>Moderate disease activity</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>11-22</span></p>
  </td>
 </tr>
 <tr>
  <td width=189 valign=top style='width:5.0cm;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>High disease activity</span></p>
  </td>
  <td width=104 valign=top style='width:78.0pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>&gt; 22</span></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<h2><span lang=EN-US>Key Issues for Nursing care</span></h2>
<p class=MsoNormal><span lang=EN-US>Patients with inflammatory arthritis should
be seen by a doctor whenever possible, given how uncommon it is in the Gambia. </span></p>
<h2><span lang=EN-US>References</span></h2>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>National Institute
for Health and Care Excellence (2009). Rheumatoid arthritis in
adulte:management. NICE guideline (CG79).</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Ally, Meyer and
Anderson (2016). Early rheumatoid arthritis: focus on RA in the developing
world. South African Family Practice 2016; 58(4):164-166.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Singh et al
(2016). 2015 American College of Rheumatology Guideline for the treatment of
rheumatoid arthritis. Arthritis Care and Research 2016; 68(1):1-25.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Smolen and Aletaha
(2018). Assessment of rheumatoid arthritis activity in clinical trials and
clinical practice. Up To Date. </span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Written by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Karen Forrest</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 22 May 2018</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Reviewed by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Fatai Akemokwe</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 17 June 2018 </span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Version:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Change history:</span></b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Review due date:</span></b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>1.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>New document</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>15 August 2020</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>1.1</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Executive summary added</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>15 August 2020</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Review Comments (<i>if applicable)</i></span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>&nbsp;</span></b></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
</div>
</div><!-- /content -->

</div>

</body>
</html>
